Walgreens Boots Alliance (WBA)
(Delayed Data from NSDQ)
$17.60 USD
-0.21 (-1.18%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $17.60 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
WBA 17.60 -0.21(-1.18%)
Will WBA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for WBA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WBA
Walgreens Boots Alliance, Inc. (WBA) Is a Trending Stock: Facts to Know Before Betting on It
Stock Market News for Apr 11, 2024
WBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insiders Are Buying These 5 Stocks
Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
Other News for WBA
Walgreens Boots Alliance Declares Quarterly Dividend
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys
Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
Peering Into Walgreens Boots Alliance's Recent Short Interest